Teva Pharmaceutical Industries Limited (TEVA)
| Market Cap | 11.70B |
| Revenue (ttm) | 15.27B |
| Net Income (ttm) | -2.21B |
| Shares Out | 1.12B |
| EPS (ttm) | -1.98 |
| PE Ratio | n/a |
| Forward PE | 4.28 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 3,444,164 |
| Open | 10.40 |
| Previous Close | 10.47 |
| Day's Range | 10.40 - 10.51 |
| 52-Week Range | 7.09 - 11.45 |
| Beta | 1.19 |
| Analysts | Buy |
| Price Target | 12.50 (+19.73%) |
| Earnings Date | Feb 7, 2024 |
About TEVA
Teva Pharmaceutical Industries Limited, a pharmaceutical company, develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. The company offers sterile products, hormones, high-potency drugs, and cytotoxic substances in various dosage forms, including tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams. It also manufactures and sells active pharmaceutical ingredients, as well as provides ... [Read more]
Full Company ProfileFinancial Performance
Financial StatementsAnalyst Forecast
According to 7 analysts, the average rating for TEVA stock is "Buy." The 12-month stock price forecast is $12.5, which is an increase of 19.73% from the latest price.
News
Teva to Present at the 42nd Annual J.P. Morgan Healthcare Conference
TEL AVIV, Israel--(BUSINESS WIRE)--Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that Richard Francis, Teva's President and CEO, will present at the 42nd Annual J.P. Morgan...
Election noise may make pharmaceutical stocks 'untenable' for investors, says Mizuho's Jared Holz
Jared Holz, Mizuho healthcare sector specialist, joins 'The Exchange' to discuss the 2024 outlook for health care, which stocks to buy in the new year, and more.
Teva and Biolojic Design Announce Exclusive License Agreement for the Development of a Therapeutic Antibody for Atopic Dermatitis and Asthma
TEL AVIV, Israel--(BUSINESS WIRE)--Teva Pharmaceutical Industries Ltd., (NYSE and TASE:TEVA) and Biolojic Design Ltd. ("Biolojic"), a biotechnology company that uses computational biology and artifici...
New Post Hoc Phase 3 Data Analysis Shows AJOVY® (fremanezumab) Reduced Migraine Attacks in Adults with Migraine and Co-morbid Obesity
TEL AVIV, Israel--(BUSINESS WIRE)--Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announces that a post hoc analysis4 of two phase 3 clinical studies presented today at the European Headach...
Teva Pharma is the way to play the re-rise of generic drugs
Generic and specialty pharmaceutical company Teva Pharmaceutical Industries Ltd. NYSE: TEVA stock has underperformed for nearly a decade.
Teva to Present at the 6th Annual Evercore ISI HealthCONx Conference
TEL AVIV, Israel--(BUSINESS WIRE)--Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that Richard Francis, Teva's President and CEO, will present at the Evercore ISI HealthCONx...
Teva Announces Approval of a Generic Version of Forteo® (teriparatide injection), in the U.S.
PARSIPPANY, N.J. & TEL AVIV, Israel--(BUSINESS WIRE)--Teva Pharmaceuticals Inc., a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), announced today the approval of a generi...
MedinCell Applauds Teva and Royalty Pharma Collaboration to Further Accelerate Olanzapine LAI Program (Codename: mdc-TJK or TEV-‘749)
MONTPELLIER, France--(BUSINESS WIRE)--Regulatory News: MedinCell (Paris:MEDCL): In a joint press release announcing the financing agreement: Richard Francis, President and CEO of Teva said: “Since lau...
Tel Aviv-based Teva CEO: Our manufacturing is unaffected as it stands
Teva CEO Richard Francis joins 'Squawk on the Street' to discuss how the company has been able to manage business operations, how the company's employees are faring, and more.
Teva shares climb as third-quarter sales top estimates
Teva Pharmaceutical Industries Ltd.'s American depositary receipts TEVA, -0.11% gained 3% premarket on Wednesday after the company reported third-quarter sales that topped expectations and raised its ...
Teva Pharm Q3 profit rises, sees higher 2023 revenue
Teva Pharmaceutical Industries reported slightly higher third-quarter profit, helped by sales of its Austedo treatment for Huntington's Disease, and said production in Israel was unaffected by the cou...
Teva Reports Third Quarter 2023 Financial Results and Increases Revenue Guidance
TEL AVIV, Israel--(BUSINESS WIRE)--Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today reported results for the quarter ended September 30, 2023. Mr. Richard Francis, Teva's President and ...
Teva appoints new CEO for Teva api, its Active Pharmaceutical Ingredients Business
TEL AVIV, Israel--(BUSINESS WIRE)--Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced the appointment of Dr. R. Ananthanarayanan (Ananth) as CEO of its Teva Active Pharmaceutica...
Teva to Present New Data Supporting Safety, Efficacy and Real-World Effectiveness of AUSTEDO® (deutetrabenazine) Tablets at the 2023 HSG Annual Meeting
TEL AVIV, Israel & PARSIPPANY, N.J.--(BUSINESS WIRE)--Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced new HD data will be presented...
Teva to Provide Second Round of Funding to Clinics in California, Florida and New Jersey as Part of $2 Million Commitment Through Community Routes: Access to Mental Health Care Program
SANTA BARBARA, Calif. & PARSIPPANY, N.J.--(BUSINESS WIRE)--Direct Relief, the National Association of Free and Charitable Clinics (NAFC), and Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceuti...
Teva Phase IV UNITE Study Shows AJOVY® (fremanezumab) Reduced Migraine Attacks and Depression Symptoms in Migraine Sufferers with Major Depressive Disorder
TEL AVIV, Israel--(BUSINESS WIRE)--Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announce that data from the UNITE study presented today at the World Congress of Neurology in Montreal, Can...
Teva Leverages Market-leading Temperature and Theft Tracking from FourKites to Deliver Critical Medicines Around the World
AMSTERDAM--(BUSINESS WIRE)--Leading supply chain visibility provider FourKites today announced that Teva, a global leader in generic and innovative medicines, has achieved a 0.005% incident rate by le...
Teva Leverages Market-leading Temperature & Theft Tracking from FourKites to Deliver Critical Medicines Around the World
AMSTERDAM--(BUSINESS WIRE)--FourKites today announces that Teva, a global leader in generic and innovative medicines has achieved a 0.005% incident rate by leveraging FourKites' global carrier visibil...
Drugmaker Teva does not see big impact on business from Israel-Hamas war
Israel's war with Hamas is not expected to have much impact on Teva Pharmaceutical Industries' business performance, the company said on Tuesday.
Teva to Host Conference Call to Discuss Third Quarter 2023 Financial Results at 8 a.m. ET on November 8, 2023
TEL AVIV, Israel--(BUSINESS WIRE)--Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today that it will issue a press release on its third quarter 2023 financial results on Wednesday...
Teva partnership with Sanofi ‘will pay dividends,' analyst says
Teva Pharmaceutical Industries Ltd.'s TEVA, -4.10% new collaboration with Sanofi SNY, on an inflammatory bowel disease treatment “will pay dividends” from a commercial perspective, Evercore ISI analys...
Sanofi to co-develop Teva Pharmaceutical's Colitis, Crohn's drug
Teva Pharmaceutical Industries said on Wednesday it will collaborate with French drugmaker Sanofi to co-develop its treatment for ulcerative colitis and Crohn's disease that it expects to ultimately b...
Sanofi and Teva Announce Exclusive Collaboration to Deliver Inflammatory Bowel Disease Treatment
PARIS & PARSIPPANY, N.J--(BUSINESS WIRE)--Sanofi (EURONEXT: SAN and NASDAQ: SNY) and Teva Pharmaceuticals, a U.S. subsidiary of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announce today...
Press Release - Sanofi and Teva announce exclusive collaboration to deliver inflammatory bowel disease treatment
Sanofi and Teva announce exclusive collaboration to deliver inflammatory bowel disease treatment